CDKN3高表达促进胃癌细胞的迁移和侵袭：基于调控p53/NF-κB信号通路和抑制胃癌细胞凋亡

doi:10.12122/j.issn.1673-4254.2025.04.21

摘要/Abstract

摘要：

目的探究周期蛋白依赖性激酶抑制因子3（CDKN3）在胃癌中的表达情况，并分析其影响胃癌患者预后的潜在作用机制。方法纳入114例胃癌患者资料，分析CDKN3在胃癌组织中表达水平及其对胃癌患者术后5年生存率的影响；GO及KEGG富集分析预测CDKN3的生物学功能及可能的作用机制；通过慢病毒转染技术干预CDKN3的表达。采用Transwell、CCK-8、TUNEL染色、流式细胞术及Western blotting验证生物学功能。结果 CDKN3在胃癌组织的表达水平显著高于癌旁组织（P<0.01），且CDKN3的表达水平与CEA、CA19-9、T分期及N分期相关（P<0.05）。单因素联合多因素分析显示，CDKN3高表达是影响胃癌患者术后5年生存率的独立风险因子（P<0.05）且CDKN3高表达对胃癌患者远期预后具有预判价值（P<0.01）。生物信息学富集分析提示CDKN3的功能可能与凋亡有关。Transwell实验结果显示，下调CDKN3可抑制胃癌细胞迁移、侵袭，上调则反之（P<0.01）。TUNEL染色结果显示，癌旁组织中细胞凋亡水平高于胃癌组织（P<0.01）。CCK-8和流式结果显示，降低CDKN3表达可抑制胃癌细胞的增殖，升高胃癌细胞凋亡率（P<0.05）。Western blotting结果显示过表达CDKN3后，p53、p21和促凋亡蛋白Bax表达降低，p-p65和抗凋亡蛋白Bcl-2表达升高（P<0.05）。结论 CDKN3在胃癌组织中高表达并影响患者预后，其可能通过p53/NF-κB信号通路调控胃癌细胞凋亡并抑制其增殖、侵袭与迁移有关。

关键词: 胃癌, CDKN3, 凋亡, 增殖, 预后, p53/NF-κB

Abstract:

Objective To investigate the expression of CDKN3 in gastric cancer and its impact on prognosis of gastric cancer patients. Methods We analyzed CDKN3 expression in clinical specimens from 114 gastric cancer patients and assessed its association with 5-year postoperative survival of the patients. GO and KEGG enrichment analyses were used to predict the biological function and possible mechanism of CDKN3. The effects of lentivirus-mediated CDKN3 knockdown on biological behaviors of gastric cancer cells were evaluated using Transwell assay, CCK-8 assay, TUNEL staining, flow cytometry, and Western blotting. Results CDKN3 expression was significantly higher in gastric cancer tissues than in the adjacent tissues with significant correlations with CEA level, CA19-9 level, and T and N staging (P<0.05). High CDKN3 expression was an independent risk factor affecting 5-year postoperative survival of the patients and predictive for long-term prognosis (P<0.01). Enrichment analyses suggested a probable association of CDKN3 with apoptosis. In MGC-803 cells, CDKN3 knockdown significantly lowered migration and invasion capacities of the cells, while CDKN3 overexpression produced the opposite effects. TUNEL staining revealed a significantly lower level of cell apoptosis in gastric cancer tissues than in adjacent tissues (P<0.01). CDKN3 knockdown obviously inhibited proliferation and increased apoptosis of MGC-803 cells. CDKN3 overexpression down-regulated the expressions of p53, p21 and Bax and up-regulated the expressions of p-p65 and Bcl-2. Conclusion CDKN3 is highly expressed in gastric cancer tissues and affects patient prognosis. CDKN3 overexpression promotes proliferation, invasion and migration and suppressed apoptosis of gastric cancer cells possibly through the p53/NF-κB signaling pathway.

Key words: gastric cancer, CDKN3, apoptosis, proliferation, prognosis, p53/NF-κB

张毅, 沈昱, 万志强, 陶嵩, 柳亚魁, 王栓虎. CDKN3高表达促进胃癌细胞的迁移和侵袭：基于调控p53/NF-κB信号通路和抑制胃癌细胞凋亡[J]. 南方医科大学学报, 2025, 45(4): 853-861.

Yi ZHANG, Yu SHEN, Zhiqiang WAN, Song TAO, Yakui LIU, Shuanhu WANG. High expression of CDKN3 promotes migration and invasion of gastric cancer cells by regulating the p53/NF-κB signaling pathway and inhibiting cell apoptosis[J]. Journal of Southern Medical University, 2025, 45(4): 853-861.

图/表 11

图1 CDKN3在胃癌及癌旁组织中的表达情况

Fig.1 Expression of CDKN3 in gastric cancer (GC) and adjacent tissues. A: Immunohistochemistry of CDKN3 in gastric cancer (GC) and adjacent tissues. B: Relative IOD values of CDKN3 expression. **P<0.01.

表1 CDKN3表达量与胃癌患者临床病理参数间的关系

Tab.1 Relationship between the expression level of CDKN3 in GC tissues and clinicopathological parameters of the patients

Clinicopatholological parameters	n	CDKN3		χ²	P
Clinicopatholological parameters	n	Low expression (n=57)	High expression (n=57)	χ²	P
Gender
Male	81	43 (53.09%)	38 (46.91%)	1.066	0.302
Female	33	14 (42.42%)	19 (57.58%)	1.066	0.302
Age (year)
<60	46	22 (47.83%)	24 (52.17%)	0.146	0.703
≥60	68	35 (51.47%)	33 (48.53%)	0.146	0.703
CEA (μg/L)
<5	69	46 (66.67%)	23 (33.33%)	19.422	<0.001
≥5	45	11 (24.44%)	34 (75.56%)	19.422	<0.001
CA19-9 (kU/L)
<37	86	53 (61.63%)	33 (38.37%)	18.937	<0.001
≥37	28	4 (14.29%)	24 (85.71%)	18.937	<0.001
Tumor size (cm)
<5	67	38 (56.72%)	29 (43.28%)	2.932	0.087
≥5	47	19 (40.43%)	28 (59.57%)	2.932	0.087
Histological type
Adenocarcinoma	104	53 (50.96%)	51 (49.04%)	0.438	0.508
Other	10	4 (40.00%)	6 (60.00%)	0.438	0.508
Grade of differentiation
Well	10	4 (40.00%)	6 (60.00%)	4.001	0.135
Moderate	38	24 (63.16%)	14 (36.84%)
Poor	66	29 (43.94%)	37 (56.06%)
T Stage
T₁-T₂	37	24 (64.86%)	13 (35.14%)	4.842	0.028
T₃-T₄	77	33 (42.86%)	44 (57.14%)	4.842	0.028
N Stage
N₀-N₁	71	41 (57.75%)	30 (42.25%)	4.518	0.034
N₂-N₃	43	16 (37.21%)	27 (62.79%)	4.518	0.034

图2 胃癌组织中CDKN3表达水平与CA19-9及CEA的相关性分析

Fig.2 Correlation analysis between the expression level of CDKN3 in GC and the levels of CA19-9 and CEA in peripheral blood. A: Correlation analysis between CDKN3 and CA19-9. B: Correlation analysis between CDKN3 and CEA.

图3 胃癌组织中CDKN3表达量与患者远期预后之间的关系

Fig.3 Correlation of the expression level of CDKN3 in gastric cancer tissues with long-term prognosis of the patients.

表2 影响胃癌根治术后5年生存率的单因素及多因素分析

Tab.2 Univariate and multivariate analyses of the factors affecting the 5-year survival rate after radical gastrectomy for gastric cancer patients

Factors	Univariate analysis		Multivariate analysis
Factors	Log-rank χ²	P	HR	95% CI	P
Gender (female vs male)	0.108	0.742	-	-	-
Age (≥60 years vs <60 years)	0.162	0.687	-	-	-
CDKN3 expression (high vs low)	34.036	<0.001	2.819	1.396-5.692	0.004
CEA(≥5 μg/L vs <5 μg/L)	20.961	<0.001	1.954	1.084-3.522	0.026
CA19-9 (≥37 kU/L vs <37 kU/L)	22.695	<0.001	1.847	1.048-3.257	0.034
Tumor size (≥5 cm vs <5 cm)	6.139	0.013	0.978	0.552-1.730	0.938
Histological type (other vs adenocarcinoma)	0.309	0.578	-	-	-
Grade of differentiation (well vs moderate vs poor)	5.623	0.060	-	-	-
T Stage (T₃-T₄vs T₁-T₂)	13.586	<0.001	2.438	1.160-5.120	0.019
N Stage (N₂-N₃vs N₀-N₁)	20.178	<0.001	2.099	1.177-3.744	0.012
HR: Hazard ratio; CI: Confidence interval.

图4 对胃癌患者预后的评估价值

Fig.4 Assessment of the prognostic value of CDKN3 for gastric cancer patients.

图5 CDKN3促进胃癌细胞的迁移与侵袭

Fig.5 CDKN3 overexpression promotes gastric cancer cell migration and invasion. A,B: The expression of CDKN3 protein after lentivirus transfection was detected by Western blotting. C:Transwell experiment for analyzing the impact of CDKN3 on the migration and invasion abilities of MGC803 cells. D: Quantitative analysis of the number of migrated cells. E: Quantitative analysis of the number of invaded cells. *P<0.05, **P<0.01 vs control.

图6 CDKN3的KEGG和GO富集分析

Fig.6 KEGG and GO enrichment analysis of CDKN3. A: KEGG analysis of CDKN3 in gastric cancer. B: GO analysis of CDKN3 in gastric cancer.

图7 TUNEL染色检测胃癌及癌旁组织中细胞凋亡情况

Fig.7 TUNEL staining was used to detect cell apoptosis in gastric cancer and adjacent tissues. A,B: TUNEL staining and scoring of apoptosis in gastric cancer tissues sections and adjacent tissues sections. **P<0.01vs gastric cancer. GC: Gastric cancer.

图8 CDKN3对胃癌细胞凋亡和增殖的影响

Fig.8 Effect of CDKN3 on apoptosis and proliferation of MGC803 cells. A,B: Cell apoptosis rate detected by flow cytometry after lentivirus transfection. C: Expression of Bcl-2 and Bax in MGC803 cells. D: Quantitative analysis of Bcl-2/Bax ratio. E: Effect of CDKN3 on proliferation of MGC-803 cells. *P<0.05, **P<0.01 vs control.

图9 CDKN3对胃癌细胞p53/NF-κB信号通路的影响

Fig.9 Effect of CDKN3 on p53/NF-κB signaling in MGC803 cells. A: Expression of p53, p21, p65 and p-p65 in MGC803 cells. B, C: Quantitative analysis of p53, p21, p65 and p-p65 ratio. *P<0.05, **P<0.01 vs control.

参考文献 33

1	Yang L, Ying X, Liu S, et al. Gastric cancer: Epidemiology, risk factors and prevention strategies[J]. Chin J Cancer Res, 2020, 32(6): 695-704.
2	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-63.
3	Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies[J]. Int J Mol Sci, 2020, 21(11): E4012.
4	Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-49.
5	Li WH, Zhang L, Wu YH. CDKN₃ regulates cisplatin resistance to colorectal cancer through TIPE1[J]. Eur Rev Med Pharmacol Sci, 2020, 24(7): 3614-23.
6	Dai W, Miao H, Fang S, et al. CDKN₃ expression is negatively associated with pathological tumor stage and CDKN₃ inhibition promotes cell survival in hepatocellular carcinoma[J]. Mol Med Rep, 2016, 14(2): 1509-14.
7	Dai W, Fang S, Cai G, et al. CDKN₃ expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma in vitro [J]. J Int Med Res, 2020, 48(7): 300060520936879.
8	Chang SL, Chen TJ, Lee YE, et al. CDKN₃ expression is an independent prognostic factor and associated with advanced tumor stage in nasopharyngeal carcinoma[J]. Int J Med Sci, 2018, 15(10): 992-8.
9	Wang J, Che W, Wang W, et al. CDKN₃ promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer[J]. Cancer Manag Res, 2019, 11: 3253-64.
10	李苗苗, 王海啸, 陶国全. CDKN₃基因在肝癌中的表达及其对肝癌细胞生长、细胞周期的影响[J]. 山西医科大学学报, 2016, 47(6): 496-501.
11	朱慧, 陆欢平, 李天佑, 等. CDKN₃在口腔鳞状细胞癌中的预后价值及免疫细胞浸润分析[J]. 国际检验医学杂志, 2024, 45(11): 1302-1307.
12	胡赞, 孙锐, 程方雄, 等. 胰腺癌中细胞周期依赖激酶抑制剂3的表达及意义[J]. 实用医学杂志, 2018, 34(20): 3403-5.
13	de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403.
14	Ma J, Zhou W, Yuan Y, et al. PSMD12 interacts with CDKN₃ and facilitates pancreatic cancer progression[J]. Cancer Gene Ther, 2023, 30(8): 1072-83.
15	Srinivas V, Kitagawa M, Wong J, et al. The tumor suppressor Cdkn3 is required for maintaining the proper number of centrosomes by regulating the centrosomal stability of Mps1[J]. Cell Rep, 2015, 13(8): 1569-77.
16	Zhang CL, Shen Q, Gao MQ, et al. The role of Cyclin Dependent Kinase Inhibitor 3 (CDKN₃) in promoting human tumors: Literature review and pan-cancer analysis[J]. Heliyon, 2024, 10(4): e26061.
17	Li Y, Ji S, Fu LY, et al. Knockdown of cyclin-dependent kinase inhibitor 3 inhibits proliferation and invasion in human gastric cancer cells[J]. Oncol Res, 2017, 25(5): 721-31.
18	Zhou Y, Bian S, Zhou X, et al. Single-cell multiomics sequencing reveals prevalent genomic alterations in tumor stromal cells of human colorectal cancer[J]. Cancer Cell, 2020, 38(6): 818-28. e5.
19	Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance[J]. Cancer Cell, 2019, 35(3): 347-67.
20	Yan CS, Zheng L, Jiang ST, et al. Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity[J]. Cancer Cell, 2023, 41(7): 1276-93.e11.
21	米贤良, 魏子白, 杨长青. 基于生物信息学分析胃癌与癌旁组织中差异基因的表达[J]. 现代消化及介入诊疗, 2022, 27(11): 1419-23.
22	Ucaryilmaz Metin C, Ozcan G. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer[J]. BMC Cancer, 2022, 22(1): 692.
23	Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies[J]. Aging: Albany NY, 2016, 8(4): 603-19.
24	Patriarca C, Pini GM, Conti G. Invasion and metastasis: a historical perspective[J]. Pathologica, 2020, 112(4): 229-33.
25	Park W, Wei S, Kim BS, et al. Diversity and complexity of cell death: a historical review[J]. Exp Mol Med, 2023, 55(8): 1573-94.
26	Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications[J]. Nat Rev Mol Cell Biol, 2020, 21(11): 678-95.
27	Vaghari-Tabari M, Ferns GA, Qujeq D, et al. Signaling, metabolism, and cancer: an important relationship for therapeutic intervention[J]. J Cell Physiol, 2021, 236(8): 5512-32.
28	Herriage HC, Huang YT, Calvi BR. The antagonistic relationship between apoptosis and polyploidy in development and cancer[J]. Semin Cell Dev Biol, 2024, 156: 35-43.
29	Hadian K, Stockwell BR. The therapeutic potential of targeting regulated non-apoptotic cell death[J]. Nat Rev Drug Discov, 2023, 22(9): 723-42.
30	Kumar S, Dorstyn L, Lim Y. The role of caspases as executioners of apoptosis[J]. Biochem Soc Trans, 2022, 50(1): 33-45.
31	Li MM, Yang JY, Li J, et al. Epiberberine induced p53/p21-dependent G2/M cell cycle arrest and cell apoptosis in gastric cancer cells by activating γ‑aminobutyric acid receptor‑β3[J]. Phytomedicine, 2024, 123: 155198.
32	艾亚楠, 赵唯含. NF-κB信号通路在胃癌前病变中的发病机制及中西医治疗的研究进展[J]. 中国实验方剂学杂志, 2022, 28(24): 237-43.
33	Schäfer C, Göder A, Beyer M, et al. Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells[J]. Cell Signal, 2017, 29: 218-25.

[1]	陈悦, 肖林雨, 任侣, 宋雪, 李静, 胡建国. 水晶兰苷通过抑制PI3K/AKT信号通路减少神经元凋亡改善脊髓损伤后小鼠的运动功能[J]. 南方医科大学学报, 2025, 45(4): 774-784.
[2]	储菲, 陈孝华, 宋博文, 杨晶晶, 左芦根. 苏荠宁黄酮通过抑制PI3K/AKT信号通路拮抗肠上皮细胞凋亡改善小鼠实验性结肠炎[J]. 南方医科大学学报, 2025, 45(4): 819-828.
[3]	岳雅清, 牟召霞, 王希波, 刘艳. Aurora-A过表达通过激活NF-κBp65/ARPC4信号轴促进宫颈癌细胞的侵袭和转移[J]. 南方医科大学学报, 2025, 45(4): 837-843.
[4]	庆顺杰, 沈智勇. 过表达己糖激酶2通过激活JAK/STAT途径促进结直肠癌细胞的增殖、迁移和侵袭并调节肿瘤免疫微环境[J]. 南方医科大学学报, 2025, 45(3): 542-553.
[5]	黄晴晴, 张文静, 张小凤, 王炼, 宋雪, 耿志军, 左芦根, 王月月, 李静, 胡建国. 高表达MYO1B促进胃癌细胞增殖、迁移和侵袭并与患者的不良预后有关[J]. 南方医科大学学报, 2025, 45(3): 622-631.
[6]	李华莉, 宋婷, 刘嘉雯, 李永宝, 姜兆静, 窦文, 周凌宏. 预后导向的肺癌调强放疗计划优化新方法[J]. 南方医科大学学报, 2025, 45(3): 643-649.
[7]	宋雪, 陈悦, 张敏, 张诺, 左芦根, 李静, 耿志军, 张小凤, 王月月, 王炼, 胡建国. GPSM2在胃癌组织中高表达并通过促进肿瘤细胞的增殖影响患者预后[J]. 南方医科大学学报, 2025, 45(2): 229-238.
[8]	陈镝, 吕莹, 郭怡欣, 张怡荣, 王蕊璇, 周小若, 陈雨欣, 武晓慧. 双氢青蒿素可显著增强阿霉素诱导的三阴性乳腺癌细胞凋亡：基于负向调控STAT3/HIF-1α通路[J]. 南方医科大学学报, 2025, 45(2): 254-260.
[9]	邹金华, 王惠, 张冬艳. SLC1A5通过促进M2型巨噬细胞极化促进肝癌进展[J]. 南方医科大学学报, 2025, 45(2): 269-284.
[10]	宾禹, 李子雯, 左素微, 孙思诺, 李敏, 宋佳茵, 林旭, 薛刚, 吴靖芳. 载脂蛋白C1高表达通过激活JAK2/STAT3信号通路促进甲状腺乳头状癌细胞的增殖并抑制凋亡[J]. 南方医科大学学报, 2025, 45(2): 359-370.
[11]	曹周芳, 汪元, 王梦娜, 孙玥, 刘菲菲. LINC00837/miR-671-5p/SERPINE2功能轴促进类风湿关节炎成纤维细胞样滑膜细胞的恶性病理学过程[J]. 南方医科大学学报, 2025, 45(2): 371-378.
[12]	唐天威, 李路安, 陈源汉, 张丽, 徐丽霞, 李志莲, 冯仲林, 张辉林, 华瑞芳, 叶智明, 梁馨苓, 李锐钊. 高血清胱抑素C水平是IgA肾病不良预后的独立危险因素[J]. 南方医科大学学报, 2025, 45(2): 379-386.
[13]	陈晓睿, 魏青政, 张宗亮, 原江水, 宋卫青. 过表达带电多泡体蛋白2B基因抑制肾透明细胞癌细胞的增殖[J]. 南方医科大学学报, 2025, 45(1): 126-136.
[14]	王耀彬, 陈柳燕, 罗伊凌, 申继清, 周素芳. NUF2对泛癌的预后和免疫治疗效果的预测价值[J]. 南方医科大学学报, 2025, 45(1): 137-149.
[15]	周超, 张晶晶, 唐巧, 付双楠, 张宁, 何召云, 张瑾, 张田义, 刘鹏程, 宫嫚. 血清色氨酸用于乙肝相关慢加急性肝衰竭90 d死亡风险分层管理的潜在价值：一项多中心回顾性研究[J]. 南方医科大学学报, 2025, 45(1): 59-64.